LBRX vs LCTX

LB Pharmaceuticals Inc vs Lineage Cell Therapeutics, Inc. — Valuation Comparison 2026

LBRX

Biotechnology
LB Pharmaceuticals Inc
Quality
4.6
out of 10
Value Trap
Price
$27.53
Last close
Models
7/13
Active
VS

LCTX

Biotechnology
Lineage Cell Therapeutics, Inc.
Quality
6.7
out of 10
Value Trap
24
SAFE
Price
$1.33
Last close
Models
9/13
Active

Model-by-Model Comparison

ModelType LBRX Fair ValueLBRX Upside LCTX Fair ValueLCTX Upside
Bayesian DCF Intrinsic $11.21 -59.3% $0.34 -74.5%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $9.44 -65.7% $0.23 -82.9%
Dynamic NAV Asset-Based $8.72 -68.3% $0.24 -82.3%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for LBRX vs LCTX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

LBRX vs LCTX — Which Stock Is More Undervalued?

LCTX scores higher with a 6.7/10 quality rating vs LBRX's 4.6/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing LB Pharmaceuticals Inc (LBRX) and Lineage Cell Therapeutics, Inc. (LCTX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

LBRX currently trades at $27.53 with a QOC of 4.6/10, while LCTX trades at $1.33 with a QOC of 6.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).